➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
McKinsey
Merck
Harvard Business School
Dow

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GABAPENTIN ENACARBIL

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Gabapentin Enacarbil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00311363 ↗ Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome. Completed XenoPort, Inc. Phase 3 2006-04-01 The primary objective of this trial is to assess the maintenance of efficacy of gabapentin enacarbil (GEn, XP13512) taken once daily in the long-term treatment of patients suffering from Restless Legs Syndrome (RLS).
NCT00333359 ↗ XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome. Completed XenoPort, Inc. Phase 3 2006-06-01 The primary objective of this trial is to assess the long-term safety and efficacy of XP13512 (Gabapentin Enacarbil) taken once daily for the treatment of patients suffering from Restless Legs Syndrome (RLS).
NCT00365352 ↗ XP13512 vs. Placebo in Patients With Restless Legs Syndrome. Completed XenoPort, Inc. Phase 3 2006-08-01 The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).
NCT00617461 ↗ A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment Completed XenoPort, Inc. Phase 2 2008-03-01 The purpose of this study is evaluate the difference between two doses of gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn, on pain associated with post-herpetic neuralgia.
NCT00619476 ↗ A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN) Completed XenoPort, Inc. Phase 2 2008-02-01 The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN).
NCT00643760 ↗ A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN) Completed XenoPort, Inc. Phase 2 2008-03-01 The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with diabetic peripheral neuropathy(DPN)
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gabapentin Enacarbil

Condition Name

Condition Name for Gabapentin Enacarbil
Intervention Trials
Restless Legs Syndrome 12
Restless Legs Syndrome (RLS) 4
RLS 3
Neuralgia, Postherpetic 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Gabapentin Enacarbil
Intervention Trials
Restless Legs Syndrome 20
Psychomotor Agitation 13
Syndrome 12
Neuralgia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Gabapentin Enacarbil

Trials by Country

Trials by Country for Gabapentin Enacarbil
Location Trials
United States 147
Japan 12
Germany 7
Canada 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Gabapentin Enacarbil
Location Trials
Texas 11
California 9
Florida 7
Pennsylvania 7
New York 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Gabapentin Enacarbil

Clinical Trial Phase

Clinical Trial Phase for Gabapentin Enacarbil
Clinical Trial Phase Trials
Phase 4 8
Phase 3 5
Phase 2 5
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Gabapentin Enacarbil
Clinical Trial Phase Trials
Completed 17
Recruiting 8
Active, not recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Gabapentin Enacarbil

Sponsor Name

Sponsor Name for Gabapentin Enacarbil
Sponsor Trials
XenoPort, Inc. 18
Astellas Pharma Inc 6
The Cleveland Clinic 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Gabapentin Enacarbil
Sponsor Trials
Industry 24
Other 6
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
McKinsey
Harvard Business School
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.